Saturday 17 October 2026
Export LBPS’s income statement to Excel — free account
4D pharma PLC Sponsored ADR
LBPS Healthcare Biotechnology
Revenue growth for five consecutive years.
Follow LBPS
| Dec '21 | Feb '21 | Dec '20 | Feb '20 | Dec '19 | Feb '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
P/S ratio |
697.71 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | (9.27) | (11.30) | (11.30) | — | (6.18) | — | — |
P/Operating CF |
(51.89) | (6.69) | (6.29) | (24.94) | (24.21) | — | (68.73) | — | — |
Beneish M-Score |
— | — | (2.02) | — | (47.36) | — | — | — | — |
P/B ratio |
31.35 | 4.63 | 4.36 | 138.85 | 21.88 | — | 3.54 | — | — |
Price to Tangible BV |
76.45 | 9.40 | 8.87 | 0.00 | 55.76 | — | 0.00 | — | — |
EV/Sales |
692.37 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
EV/Operating CF |
(10.96) | (3.13) | (3.57) | (12.28) | (14.97) | — | 0.00 | — | — |
EV/FCF |
(10.81) | (3.03) | (3.57) | (12.28) | (14.97) | — | 0.00 | — | — |
Quick Ratio |
4.56 | 1.97 | 1.97 | 1.09 | 1.86 | 13.07 | 154.46 | 10.90 | 14.60 |
Current Ratio |
5.21 | 2.45 | 2.45 | 2.28 | 2.28 | 14.38 | 14.38 | 11.60 | 15.19 |
Net Debt/EBITDA |
0.23 | 0.33 | 0.33 | (0.03) | 0.10 | 1.45 | 1.41 | 2.58 | 5.52 |
Debt/Assets |
21.59% | 0.00% | 2.22% | 3.01% | 3.01% | 0.00% | 0.05% | 0.00% | 0.00% |
Debt/Equity |
0.39 | 0.03 | 0.03 | 0.04 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.19 | 0.89 | 0.89 | 0.94 | 0.95 | 1.19 | 20.28 | 0.82 | 1.29 |
Capex/Depreciation |
(0.19) | (0.13) | (0.15) | (0.38) | (0.43) | — | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(64.13) | — | (5,111.46) | — | (501.61) | — | — | (83.96) | (36.20) |
| (89.48%) | (78.27%) | (87.26%) | (97.93%) | (167.65%) | (7.67%) | (0.03%) | (27.48%) | (12.11%) | |
| (59.20%) | (124.24%) | (67.82%) | (74.49%) | (74.02%) | (0.93%) | (0.02%) | (48.05%) | (11.07%) | |
ROIC |
(96.48%) | (77.94%) | (77.94%) | (77.69%) | (91.89%) | (6.30%) | (6.27%) | 0.00% | 0.00% |
Return on Tangible Assets |
(100.26%) | (175.12%) | (175.09%) | (218.91%) | (218.35%) | (58.60%) | (0.21%) | (35.23%) | (13.35%) |
Average Days of Receivables |
4,695.69 | 2,538.60 | 2,538.60 | 9,564.63 | 9,564.63 | — | 9,381.59 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
3,012.81% | 3,388.99% | 3,388.99% | 10,852.42% | 10,852.42% | — | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
2,212.81% | 1,886.23% | 1,886.23% | 3,858.74% | 3,858.74% | — | 163.42% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.33 | 0.00 | 0.40 | 0.46 | 0.46 | 0.00 | 0.00 | 0.00 | 0.15 |
Share Based Compensation of Revenue |
99.03% | 47.97% | 47.97% | 126.39% | 126.39% | — | 0.00% | — | — |
Graham Net Nets |
0.01 | 0.06 | 0.06 | (0.05) | 0.01 | — | (2.00) | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Earnings Yield |
(12.34%) | (3.74%) | (3.97%) | (5.00%) | (6.41%) | — | (3.64%) | — | — |
Free Cash Flow Yield |
(9.18%) | (31.01%) | (26.23%) | (8.16%) | (6.64%) | — | 0.00% | — | — |
Revenue per Share |
0.03 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
Operating CF per Share |
(1.79) | 0.00 | (1.91) | 0.00 | (0.44) | (0.30) | (0.04) | (0.35) | (0.24) |
Capex per Share |
(0.01) | 0.00 | (0.02) | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.80) | 0.00 | (1.93) | 0.00 | (0.45) | (0.30) | (0.04) | (0.35) | (0.24) |
Cash per Share |
0.99 | 0.00 | 0.84 | 0.00 | 0.08 | 0.42 | 0.08 | 1.04 | 1.31 |
Shareholders Equity per Share |
1.53 | 0.00 | 2.73 | 0.00 | 0.48 | 3.28 | 0.61 | 1.45 | 1.65 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.53 | 0.00 | 2.73 | 0.00 | 0.48 | 3.28 | 0.61 | 1.45 | 1.65 |
Free Cash Flow |
(38.19) | (27.48) | (27.50) | (29.31) | (29.38) | (0.45) | (0.29) | (22.54) | (15.74) |
Working Capital |
27.88 | 12.34 | 12.34 | 8.30 | 8.30 | 0.65 | 0.65 | 71.37 | 86.47 |
Capital Expenditures |
(0.28) | (0.21) | (0.23) | (0.63) | (0.70) | — | 0.00 | (2.81) | (2.86) |
Net Current Asset Value |
8.12 | 10.72 | 10.72 | 5.15 | 5.15 | (35.43) | (35.43) | 67.36 | 84.32 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Capex to Sales |
0.39 | 0.31 | 0.33 | 2.33 | 2.60 | — | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.37 | 0.31 | 0.31 | 0.29 | 0.29 | — | 0.00 | 0.19 | 0.16 |
Cash ROIC |
(57.80%) | (52.79%) | (52.83%) | (90.34%) | (78.46%) | (8.07%) | (5.13%) | (13.92%) | (8.21%) |
Accounts Receivable Turnover |
0.10 | 0.14 | 0.12 | 0.04 | 0.04 | — | 0.04 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.69 | 0.39 |
Inventory Turnover |
0.00 | — | 0.00 | — | 0.00 | — | 0.00 | 4.17 | 2.40 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 670.16 | 686.89 |
Days of Inventory on Hand |
0.00 | — | 0.00 | — | 0.00 | — | 88.13 | 94.04 | 140.57 |
Average Receivables |
7.02 | 4.80 | 5.92 | 7.05 | 6.98 | — | 6.37 | 4.96 | 4.96 |
Average Payables |
3.11 | 4.54 | 3.09 | 1.64 | 0.84 | 0.03 | 1.23 | 1.94 | 1.94 |
Average Inventory |
0.38 | — | 0.33 | — | 0.32 | — | 0.36 | 0.32 | 0.32 |
Average Assets |
53.95 | 24.55 | 44.96 | 40.83 | 40.98 | 41.13 | 78.07 | 57.50 | 110.03 |
Average Common Equity |
35.69 | 38.97 | 34.95 | 31.05 | 18.09 | 5.00 | 49.65 | 100.54 | 100.54 |
Columns are period end dates · fundamentals updated 5 Oct 2026